BVS · Bioventus Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $568.09M | $573.28M | $512.35M | $512.12M | $321.16M |
| Cost of Revenue | $179.93M | $185.05M | $184.15M | $181.04M | $87.64M |
| Gross Profit | $388.16M | $388.23M | $328.19M | $331.08M | $233.52M |
| R&D | $12.11M | $13.64M | $13.45M | $25.94M | $11.20M |
| SG&A | $314.03M | $340.89M | $303.88M | $332.61M | $193.08M |
| Total Operating Expenses | - | - | - | - | - |
| D&A | $47.01M | $49.55M | $57.37M | $66.80M | $28.64M |
| Operating Income | $53.98M | ($11.98M) | ($81.72M) | ($251.05M) | $21.24M |
| Interest Expense | - | - | - | - | - |
| Income Tax | ($1.56M) | ($5.29M) | $85.0K | ($50.51M) | $1.19M |
| Net Income | $22.73M | ($33.54M) | ($156.23M) | ($158.70M) | $16.41M |
| EPS - Basic | $0.34 | ($0.52) | ($2.49) | ($2.59) | ($0.15) |
| EPS - Diluted | $0.33 | ($0.52) | ($2.49) | ($2.59) | ($0.15) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $51.24M | $41.58M | $36.96M | $31.81M | $43.93M |
| Accounts Receivable | $128.30M | $127.39M | $122.79M | $136.65M | $124.96M |
| Inventory | $82.24M | $92.47M | $91.33M | $85.41M | $61.69M |
| Accounts Payable | $10.93M | $23.69M | $23.04M | $37.55M | $16.91M |
| Current Assets | $272.84M | $275.61M | $268.00M | $272.57M | $263.10M |
| Total Assets | $683.56M | $727.96M | $810.91M | $1.37B | $1.23B |
| Current Liabilities | $160.38M | $210.40M | $175.50M | $304.02M | $180.86M |
| Long-term Debt | $278.95M | $308.29M | $367.00M | $385.01M | $339.64M |
| Total Liabilities | $455.11M | $542.35M | $589.79M | $1.03B | $692.07M |
| Stockholders' Equity | $184.10M | $147.94M | $173.59M | $316.58M | $458.92M |
| Retained Earnings | ($334.93M) | ($355.08M) | ($321.54M) | ($165.31M) | ($6.60M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $74.67M | $38.80M | $15.34M | ($13.54M) | $71.80M |
| Investing Cash Flow | ($3.25M) | $22.96M | $15.81M | ($116.44M) | ($20.50M) |
| Financing Cash Flow | ($62.14M) | ($54.58M) | ($26.65M) | $62.08M | ($29.57M) |
| CapEx | $2.56M | $1.01M | $7.36M | $10.04M | $4.09M |
| Free Cash Flow | $72.11M | $37.79M | $7.98M | ($23.58M) | $67.71M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 68.3% | 67.7% | 64.1% | 64.6% | 72.7% |
| Operating margin | 9.5% | -2.1% | -16.0% | -49.0% | 6.6% |
| EBITDA margin | 17.8% | 6.6% | -4.8% | -36.0% | 15.5% |
| Net margin | 4.0% | -5.9% | -30.5% | -31.0% | 5.1% |
| Free cash flow margin | 12.7% | 6.6% | 1.6% | -4.6% | 21.1% |
| FCF / Net income | 3.17 | -1.13 | -0.05 | 0.15 | 4.13 |
| R&D / Revenue | 2.1% | 2.4% | 2.6% | 5.1% | 3.5% |
| SG&A / Revenue | 55.3% | 59.5% | 59.3% | 64.9% | 60.1% |
| Effective tax rate | -7.4% | - | - | - | 6.8% |
| Return on assets | 3.3% | -4.6% | -19.3% | -11.6% | 1.3% |
| Return on equity | 12.3% | -22.7% | -90.0% | -50.1% | 3.6% |
| Return on invested capital | 11.7% | -2.1% | -11.9% | -28.3% | 2.5% |
| Liquidity | |||||
| Current ratio | 1.70 | 1.31 | 1.53 | 0.90 | 1.45 |
| Quick ratio | 1.19 | 0.87 | 1.01 | 0.62 | 1.11 |
| Cash ratio | 0.32 | 0.20 | 0.21 | 0.10 | 0.24 |
| Leverage | |||||
| Debt / Equity | 1.52 | 2.08 | 2.11 | 1.22 | 0.74 |
| Debt / Assets | 0.41 | 0.42 | 0.45 | 0.28 | 0.28 |
| Debt / EBITDA | 2.76 | 8.20 | - | - | 6.81 |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 3.71 | 4.92 | 4.67 | 4.34 | 2.67 |
| Liabilities / Assets | 0.67 | 0.75 | 0.73 | 0.75 | 0.56 |
| Efficiency | |||||
| Asset turnover | 0.83 | 0.79 | 0.63 | 0.37 | 0.26 |
| Inventory turnover | 2.19 | 2.00 | 2.02 | 2.12 | 1.42 |
| Days sales outstanding | 82d | 81d | 87d | 97d | 142d |
| Days inventory outstanding | 167d | 182d | 181d | 172d | 257d |
| Days payable outstanding | 22d | 47d | 46d | 76d | 70d |
| Cash conversion cycle | 227d | 217d | 223d | 194d | 328d |
| Valuation | |||||
| P / E | 22.5x | - | - | - | - |
| P / B | 2.8x | 4.6x | 1.9x | 0.5x | 1.4x |
| P / S | 0.9x | 1.2x | 0.6x | 0.3x | 2.1x |
| EV / EBITDA | 7.3x | 25.1x | - | - | 19.1x |
| Growth | |||||
| Revenue growth (YoY) | -0.9% | 11.9% | 0.0% | 59.5% | - |
| Revenue CAGR (3y) | 3.5% | 21.3% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | -0.0% | 18.3% | -0.9% | 41.8% | - |
| Operating income growth (YoY) | - | 85.3% | 67.4% | - | - |
| Net income growth (YoY) | - | 78.5% | 1.6% | - | - |
| EPS growth (YoY) | - | 79.1% | 3.9% | -1626.7% | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 90.8% | 373.4% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 24.4% | -14.8% | -45.2% | -31.0% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$568.09M totalUSSegment$502.10M · 88.4%
International Segment$65.99M · 11.6%
Product / service
$502.10M totalPain Treatments$248.24M · 49.4%
Surgical Solutions$180.44M · 35.9%
Restorative Therapies$73.42M · 14.6%
Geographic
$568.09M totalUS$502.10M · 88.4%
Non Us$65.99M · 11.6%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.95
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
8/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Bioventus Inc. against the 5 most active filers in the same SIC group.